MENU
+Compare
VNDA
Stock ticker: NASDAQ
AS OF
Dec 2 closing price
Price
$4.92
Change
-$0.10 (-1.99%)
Capitalization
296.67M

VNDA Vanda Pharmaceuticals Forecast, Technical & Fundamental Analysis

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients... Show more

Industry: #Biotechnology
VNDA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for VNDA with price predictions
Dec 01, 2025

Aroon Indicator for VNDA shows an upward move is likely

VNDA's Aroon Indicator triggered a bullish signal on October 29, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 158 similar instances where the Aroon Indicator showed a similar pattern. In of the 158 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 18, 2025. You may want to consider a long position or call options on VNDA as a result. In of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for VNDA just turned positive on November 18, 2025. Looking at past instances where VNDA's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

VNDA moved above its 50-day moving average on November 25, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for VNDA crossed bullishly above the 50-day moving average on December 01, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VNDA advanced for three days, in of 250 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for VNDA moved out of overbought territory on November 19, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VNDA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VNDA broke above its upper Bollinger Band on November 18, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VNDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.624) is normal, around the industry mean (27.247). P/E Ratio (126.000) is within average values for comparable stocks, (52.214). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.890). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (1.363) is also within normal values, averaging (320.114).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VNDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
VNDA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

VNDA is expected to report earnings to rise 150.00% to -94 cents per share on February 11

Vanda Pharmaceuticals VNDA Stock Earnings Reports
Q4'25
Est.
$-0.95
Q3'25
Beat
by $0.05
Q2'25
Missed
by $0.17
Q1'25
Missed
by $0.48
Q4'24
Beat
by $0.09
The last earnings report on October 29 showed earnings per share of -37 cents, beating the estimate of -43 cents. With 511.96K shares outstanding, the current market capitalization sits at 296.67M.
A.I. Advisor
published General Information

General Information

a manufacturer of biopharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
2200 Pennsylvania Avenue NW
Phone
+1 202 734-3400
Employees
203
Web
https://www.vandapharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RNMBF1749.0049.01
+2.88%
Rheinmetall AG
CTTMF0.62N/A
N/A
Catena Media PLC
DBMG70.00N/A
N/A
DBM Global Inc.
SSPPF1.71N/A
N/A
SSP Group PLC
SDXAY10.33-0.16
-1.53%
Sodexo

VNDA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, VNDA has been loosely correlated with APLS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if VNDA jumps, then APLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VNDA
1D Price
Change %
VNDA100%
-1.99%
APLS - VNDA
43%
Loosely correlated
-2.55%
ADMA - VNDA
40%
Loosely correlated
-0.67%
IVF - VNDA
40%
Loosely correlated
-11.83%
NEVPF - VNDA
38%
Loosely correlated
N/A
OLMA - VNDA
38%
Loosely correlated
-2.86%
More